The Need for Something Better
Americans born today now have up to a 50% chance of developing cancer in their lifetime(1). Most will be unprepared to navigate the cost and access to genomic testing that can change the odds in treatment outcomes.
Cancer is a complex genetic disease.
1 in 6 adults carry a potentially health-related genetic risk, but most are unaware of their personal genetic risk factor.(2)
Understanding the genetic basis cancer can play a significant role in better outcomes and longevity. Unfortunately, gaps in healthcare services, coverage and awareness can put cancer patients at risk for misdiagnosis, uninformed treatment decisions, financial strain, and disease progression.
Cancer is challenging to navigate.
Less than 8% of adult cancer patients participate in a clinical trial.(3)
The healthcare landscape is difficult to navigate. Access to cancer genomic profiling, expert pathology review and clinical trials enrollment takes an experienced support team not typically covered by traditional health plans.
Cancer can be financially and
emotionally devastating.
Cancer patients within one year of diagnosis are about 3.5 times more likely to file for bankruptcy.
Up to 73% of cancer patients suffer financial loss and up to 42% report significant or catastrophic financial burdens as a result of high out of pocket costs.(4) Even more concerning, 38% of cancer patients postpone or do not fill drug prescriptions.(5)
Cancer Guardian bridges the healthcare gap with proven services and the latest clinical genetics testing technology.
References
1. Lifetime Risk of Developing or Dying from Cancer Basic Facts. American Cancer Society, 2019.
2. Wamberg Genomic Advisors, Cancer Survey of 204 cancer patients and nonprofessional advocates. Survey Sampling International (SSI), 2018.
3. Unger, Joseph M., et al. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical and Physician and Patient Barriers to Cancer Clinical Trial Participation. JNCI J NATL Cancer Institute, 2019.
4. Family Reach. Annual Report 2016. Family Reach Foundation https://familyreachorg/wp-content/uploads/
2017/05/ frf_2016_annual_report_compressedpdf Accessed July 30, 2017.
5. CancerCare. Cancer Care Patient Access and Engagement Report. New York: CancerCare. 2016.
6. Manchanda, Ranjit, et al. Population based germline testing for primary cancer prevention. Oncotarget, 2018, Vol. 9 (No. 69), pp: 33062-33063
7. Waszak, Przemyslaw M. et al. The Spread of Medical Fake News in Social Media. Health Policy & Technology Review, Elsevier, 2018.
8. Stephen S. Raab, Dana M. Grzybicki, CA Cancer J. Clin. 2010 May-Jun,60(3): 139-65
9. Raab, Stephen S. MD, et al. Quality in Cancer Diagnosis. Cancer J. Clinical 2010
10. J. Unger, et al., Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical and Physician Barriers to Cancer Clinical Trial Participation, JNCI J Natl Cancer Inst 2019
11. The State of Cancer Care in America, 2014: A report by the American Society of Clinical Oncology. Journal of Oncology Practice, 2014; 10(2):120-122
12. Sun Life Stop-Loss Report, 2019. https://sunlife.showpad.com/share/
7SzmNmJJs1a6msorM0DZA
14. Measuring Health-Related Productivity Loss. https://ww.liebertpubl.com/doi/pdf/10.3322/caac.20068.
16. Wamberg Genomic Advisors Cancer Survey of 204 cancer patients and nonprofessional advocates fielded by Survey Sampling International (SSI), 2018. Available at: https://www.managedhealthcareexecutive.com/leukemia-and-lymphoma/
most-troubling-part-cancer-treatment-patients
